The Science

In 1996, Dr. Wayne Lautt and his colleagues first discovered a hormone they originally called hepatic insulin-sensitizing substance (HISS). In 2021, they renamed this hormone “hepatalin”.

Through their ongoing research, Dr. Lautt and his SciMar team have determined that it is important for hepatalin and the hormone insulin to be in healthy balance. Hepatalin, when adequately produced, stimulates the body’s ability to partition glucose into muscle. When the liver does not adequately produce hepatalin, the pancreas produces additional insulin, which causes nutrient energy to be partitioned into fat.

A new understanding: type 2 diabetes is not a chronic condition; it is a state of repeated, dangerous acute responses that can be prevented and reversed. Through the lens of hepatalin, new therapies can offer type 2 diabetics new hope based on this new understanding.

Their work is keenly focused on this process of “Nutrient Partitioning” and on developing a series of “NuPa” products to measure metabolic health and to stimulate the production of hepatalin.

Science has proven so far that this essential secretion of hepatalin is hindered by stress, the lack of exercise, the consumption of sugar, and other lifestyle factors. Therefore, the goal of SciMar’s work is to determine ways for the body to always produce the right amount of hepatalin and to keep hepatalin and insulin in a healthy balance. The science suggests that when the right amount of hepatalin is present, nutrient partitioning is in balance, thereby helping people to avoid type 2 diabetes. For those already living with type 2 diabetes, managing hepatalin effectively is expected to help people avoid the disease’s worst impacts.

Changing the focus to hepatalin and nutrient partitioning will change the prevention and treatment paradigms in diabetes.

SciMar Introduces Hepatalin: A new perspective on type 2 diabetes and metabolic health (VIDEO)

Click here to read a 2021 review paper by Dr. W. Wayne Lautt.


The Research

Dr. Lautt, Professor Emeritus at the Department of Pharmacology and Therapeutics at the University of Manitoba, has about 220 peer-reviewed publications to his credit. Of these, over 60 are related to HISS, including the following:

  1. Hepatic parasympathetic (HISS) control of insulin sensitivity determined by feeding and fasting
  2. Meal-induced Insulin Sensitization in Conscious and Anesthetized Rat Models Comparing Liquid Mixed Meal with Glucose and Sucrose
  3. Synergistic Protection by S-adenosylmethionine with Vitamins C and E on Liver Injury Induced by Thioacetamide in Rats
  4. HISS-dependent Insulin Resistance (HDIR) in Aged Rats is Associated with Adiposity, Progresses to Syndrome X, and is Attenuated by a Unique Antioxidant Cocktail
  5. Meal-induced Insulin Sensitization (MIS) and its Parasympathetic Regulation in Humans
  6. Bethanechol and N-acetylcysteine Mimic Feeding Signals and Reverse Insulin Resistance in Fasted and Sucrose-induced Diabetic Rats
  7. Absence of meal-induced insulin sensitization (AMIS) in aging rats is associated with cardiac dysfunction that is protected by antioxidants
  8. Lifestyle Impact on Meal-induced Insulin Sensitization in Health and Prediabetes: a Focus on diet, antioxidants, and Exercise Interventions
  9. Obesity as an Early Symptom of the AMIS Syndrome

*In the academic literature prior to 2021, and in SciMar’s earlier materials, hepatalin was known as hepatic insulin-sensitizing substance (the “HISS” hormone).